Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Allarity Therapeutics ( (ALLR) ) is now available.
On March 2, 2026, Allarity Therapeutics entered into a note purchase agreement with Streeterville Capital under which it issued an unsecured A-1 promissory note with an original principal amount of $10.93 million and a secured B note of $10 million, with $10 million paid to the company at closing and another $10 million deposited into a controlled account of a new wholly owned subsidiary. The notes, bearing interest of 9% and 5% respectively and maturing in 18 months, are secured by a deposit account control agreement, a subsidiary guaranty, and a pledge of subsidiary interests, and they impose tight covenants restricting new debt, variable-price or highly dilutive securities, new liens, subsidiary equity issuances, and subsidiary business operations, while providing the lender with monthly redemption rights, punitive trigger and default mechanics, and the ability to accelerate repayment, underscoring both Allarity’s near-term liquidity needs and the significant control ceded to its lender.
The financing includes a mechanism allowing portions of the secured B note to be exchanged into A notes once outstanding A note principal falls below a specified threshold, offering some structural flexibility in how the debt is held and repaid. However, the combination of security interests over key assets, limitations on alternative financings, and substantial default remedies signals a highly protective structure for Streeterville Capital that may constrain Allarity’s future capital-raising options and strategic freedom while the notes remain outstanding.
The most recent analyst rating on (ALLR) stock is a Sell with a $0.84 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.
Spark’s Take on ALLR Stock
According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.
The score is weighed down primarily by weak financial performance—no revenue, ongoing losses, and sustained negative free cash flow—despite modest leverage and currently positive equity. Technicals also detract due to a clear downtrend with negative momentum, while valuation is constrained by negative earnings and lack of dividend support.
To see Spark’s full report on ALLR stock, click here.
More about Allarity Therapeutics
Allarity Therapeutics, Inc. is a Delaware-based biopharmaceutical company focused on developing cancer therapies. The company raises capital through structured financing arrangements, including promissory notes and equity purchase agreements, to fund its operations and advance its oncology pipeline in the U.S. public markets.
Average Trading Volume: 160,035
Technical Sentiment Signal: Sell
Current Market Cap: $16.4M
See more data about ALLR stock on TipRanks’ Stock Analysis page.